A recent international trial showed that patients requiring emergency heart attack treatment also benefit from further intervention to reduce the risk of future heart attacks. The study found that additional stenting for significant narrowings in other untreated arteries significantly reduces the risk of future heart attacks and death.
A new trial shows that adding a PARP inhibitor to bevacizumab improves ovarian cancer patients' chances of responding to chemotherapy. The study found median progression-free survival of 22.1 months in the olaparib arm, compared to 16.6 months in the placebo group.
A combination of ipilimumab and nivolumab has stopped or reversed melanoma progression for five years in nearly half of patients, offering new hope for advanced melanoma patients. The Checkmate 067 trial found a 52% five-year overall survival rate, with 74% treatment-free after five years.
First-line osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non-small cell lung cancer. The median overall survival with osimertinib was 38.6 months, with over half of patients alive at three years.
A new blood test has been developed to detect multiple types of cancer, including hormone receptor-negative breast, colorectal, and pancreatic cancer, with a high degree of accuracy. The test uses next-generation sequencing technology to probe DNA for methylation patterns associated with cancer.
Professional drivers, including taxi drivers, experience high levels of black carbon exposure while working in congested cities. Research found that taxi drivers are exposed to an average of 6.5 micrograms of black carbon per cubic meter of air, compared to office workers at home who experience similar levels.
The CheckMate-227 trial found that the combination of nivolumab and low-dose ipilimumab improves overall survival in patients with advanced non-small cell lung cancer compared to chemotherapy. The treatment was well-tolerated, with a low rate of discontinuation and treatment-related toxicities.
A Phase III trial validates the benefit of veliparib for patients with newly diagnosed, metastatic high-grade serous ovarian cancer. The combination therapy achieved a PFS of 23.5 months, compared to 17.3 months for the control arm.
A new treatment using niraparib after conventional chemotherapy improves progression-free survival and reduces risk of relapse or death in patients with advanced ovarian cancer. The study, led by Dr. Antonio González Martín, found a significant reduction in risk of relapse, especially in patients with homologous recombination deficiency.
A liquid biopsy test can predict which patients with colorectal cancer are likely to relapse after surgery, and guide treatment. The test identified patients who were more or less likely to remain disease-free two years after chemotherapy.
Researchers found that combination immunotherapy increases the 5-year overall survival rate to 52%, compared to 26% for ipilimumab monotherapy, and preserves quality of life. The therapy has a high cure rate and is effective even in patients who stop treatment due to side effects.